News
-
-
PRESS RELEASE
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax informs shareholders of its ordinary and extraordinary general meeting on May 30, 2024, providing access to preparatory documents and details on participation. Obefazimod and Abivax information included -
PRESS RELEASE
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax announces its annual ordinary and extraordinary general meeting on May 30, 2024, with preparatory documents available for shareholders. The meeting details, including agenda and resolutions, are accessible on the company's website -
-
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Brockhaus Technologies AG: Significant increase in revenue by 18.5% to €39.6 million and in adjusted EBITDA by 18.0% to €11.4 million (28.7% margin) in Q1 2024 – forecast 2024 unchanged
Brockhaus Technologies AG reports 18.5% revenue increase to €39.6 million and 18.0% rise in adjusted EBITDA to €11.4 million (28.7% margin) in Q1 2024. Forecast for 2024 remains unchanged